Camptosar Genetic Test Launched By Genzyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Invader assay identifies deficient UGT1A1*28 allele, which increases risk of neutropenia in colorectal cancer patients taking Camptosar.
You may also be interested in...
Camptosar Reduced Starting Dose Recommended In Patients With Genetic Marker
Patients with the deficiency of a metabolizing enzyme have an increased risk of neutropenia, revised labeling for Pfizer’s oncologic says. Patients with the deficiency should start at a lower dose, though the appropriate starting dose is not known, FDA says.
Pfizer's Camptosar To Serve As Example Of Pharmacogenetic Toxicity Risk At Meeting
Irinotecan will be used as an example of pharmacogenetic toxicity risk at Clinical Pharmacology Subcommittee meeting Nov. 3-4. Pfizer is discussing label changes with FDA regarding Camptosar use in patients with certain genotypes. Subcommittee will also address the transition of biomarkers to surrogate endpoints.
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says